SCYNEXIS Appoints Carole Sable, MD, as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Drug discovery company SCYNEXIS, Inc., today announced that it has appointed infectious disease expert Carole Sable, MD, as Chief Medical Officer. Dr. Sable was most recently a Vice President at Merck & Co., Inc, initially as franchise integrator in Infectious Diseases and more recently as VP, Project Leadership and Management in Neurosciences and Ophthalmology.
«Carole brings to SCYNEXIS a significant tenure in the clinical development of infectious disease products, both as a clinician and in various corporate roles," said Dr. Yves Ribeill, SCYNEXIS president and chief executive officer. «We look forward to her contributions as we continue to advance our lead candidate,
Prior to her recent involvement with Merck & Co., Dr. Sable served as Chief Medical Officer of Novexel SA and President of Novexel Inc., the US subsidiary, where she was responsible for clinical development and successfully filed two INDs and successfully completed Phase 2b studies for two antibacterial programs which led to the acquisition of Novexel SA by AstraZeneca. Previously, Dr. Sable was Executive Director of Infectious Disease and Vaccines Clinical Research at Merck & Co., Inc. where she was responsible for